Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-07-30 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and details changes in issued shares and treasury shares, including share repurchases and treasury share sales. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) related to disclosure of share changes. The content includes detailed tables of share repurchase transactions, prices, and confirmations of compliance with exchange rules. The document is 10,638 characters long, indicating it is a substantive report rather than a brief announcement. The focus is on share repurchase and treasury share transactions, which aligns with reporting on transactions in own shares. Therefore, the document is best classified as a 'Transaction in Own Shares' report.
2024-07-30 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. regarding a scheduled board meeting to consider and approve the interim results for the six months ended June 30, 2024, and the potential recommendation of an interim dividend. It does not contain the actual interim financial results or detailed financial data but merely notifies the market of the upcoming board meeting and the agenda. The document length is only 1326 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such announcements about upcoming board meetings to approve interim results are best classified as Regulatory Filings (RNS), since it is a general regulatory announcement and not the interim report itself.
2024-07-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations of compliance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and treasury share transactions. This fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is the report itself, not just an announcement of a report. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-07-29 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations that the repurchases were made in accordance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about transactions in the company's own shares, specifically share repurchases and treasury share changes. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length (over 11,000 characters) and detailed transactional data confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is POS with high confidence.
2024-07-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations of compliance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and treasury share transactions. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the correct classification is POS with high confidence.
2024-07-25 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations of compliance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and capital changes. This fits the definition of a 'Transaction in Own Shares' filing, which covers company buybacks or sales of its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2024-07-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.